LENZ
LENZ Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LENZ
Lenz Therapeutics, Inc.
A clinical late-stage biopharmaceutical company focused on developing innovative ophthalmic drugs for the treatment of presbyopia
Biological Technology
06/01/2017
06/25/2021
NASDAQ Stock Exchange
42
12-31
Common stock
201 Lomas Santa Fe Dr., Suite 300, Solana Beach, California 92075
--
LENZ Therapeutics, Inc., was incorporated in Ontario, Canada on June 1, 2017 and re-registered in Delaware in October 2019. They are a clinical-stage next-generation gene-editing company developing novel therapies with highly effective targeted gene integration that have the potential to cure a wide range of serious and life-threatening diseases. They are pioneering a precise method of gene editing to achieve one of the most elusive goals in medicine: to precisely "find and replace" any gene in the genome. Their next-generation gene-editing platform allows them to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined safe locations.
Earnings Call
Q1/2025
Estimate EPS-0.32
Actual EPS-0.53
Estimate Revenue--
Actual Revenue0
LENZ Therapeutics Q1 2025: Contradictions in Sample Strategy and Influencer Campaigns Unveiled
May 09,2025 10:34
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LENZ has released its 2025 Q3 earnings. EPS was reported at -0.59, versus the expected -0.69, beating expectations. The chart below visualizes how LENZ has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LENZ has released its 2025 Q3 earnings report, with revenue of 12.50M, reflecting a YoY change of NaN%, and net profit of -16.70M, showing a YoY change of -63.49%. The Sankey diagram below clearly presents LENZ's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
